Rankings
▼
Calendar
ACAD Q4 2025 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena
ACAD
ACADIA Pharmaceuticals Inc.
$4B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$284M
+9.4% YoY
Gross Profit
$258M
90.8% margin
Operating Income
$17M
6.1% margin
Net Income
$274M
96.3% margin
EPS (Diluted)
$1.60
QoQ Revenue Growth
+1.9%
Cash Flow
Operating Cash Flow
-$49M
Free Cash Flow
-$53M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$1.6B
Total Liabilities
$337M
Stockholders' Equity
$1.2B
Cash & Equivalents
$820M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$284M
$260M
+9.4%
Gross Profit
$258M
$238M
+8.4%
Operating Income
$17M
$154M
-88.7%
Net Income
$274M
$144M
+90.3%
← FY 2025
All Quarters